Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
about
Updates of prostate cancer staging: Prostate-specific membrane antigenDetection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyImpact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI.Current status of theranostics in prostate cancer.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.
P2860
Q28079444-B69AC4FD-9FD3-46FB-9119-B88FC2F88254Q31145236-5AC0CC18-1250-4D3B-BAF7-BC421C5E72F6Q33841484-F46178D4-ABF8-4845-A116-C8662DF6EE4CQ33914844-806CAFB2-43B0-43DD-B005-EAF49BD597FCQ36289592-D0E9B2CA-0710-4DE1-AAF6-BFDB407F6B97Q37626953-DE643A62-7185-4573-8802-D41BDEF54E0DQ47241139-C0CB236E-BCBD-4D60-954D-C7C6CB42BDEFQ47693515-A74EA414-A0D5-4B21-B3AC-9FA67689CCE0Q48141689-3706EF21-EF92-4290-9DD5-8EE5B8AD1E28Q48295687-42A696C9-F253-4B78-9F06-60FCEFB71EF4Q48297324-12BA984C-4E42-47B0-B747-C04FD881C91AQ50182743-D9F506D7-788E-480C-B6F1-DD395D4237AA
P2860
Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET ...... high-risk prostate carcinoma.
@en
type
label
Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET ...... high-risk prostate carcinoma.
@en
prefLabel
Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET ...... high-risk prostate carcinoma.
@en
P2093
P2860
P1476
Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET ...... high-risk prostate carcinoma.
@en
P2093
Birgit Meller
Caroline Bouter
Carsten-Oliver Sahlmann
Christian Oliver Ritter
Joachim Lotz
Johannes Meller
Lutz Trojan
Philipp Ströbel
Sameh Hijazi
P2860
P2888
P304
P356
10.1007/S00259-015-3251-Y
P577
2015-11-12T00:00:00Z